14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OVID vs PYPD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (31.1/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while OVID wins 3–2 across the 6-pillar growth and valuation breakdown. OVID trades at $2.19 (1.8x Forward P/E, -4693.7% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY).
Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OVID vs PYPD. Trailing 12-month operating profitability (OVID -4693.7% vs PYPD 0.0%) and valuation multiples (OVID 1.8x vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ OVID vs PYPD Key Questions & Quantitative Answers
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (31.1/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while OVID wins 3–2 across the 6-pillar growth and valuation breakdown. OVID trades at $2.19 (1.8x Forward P/E, -4693.7% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY). Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OVID leads the Growth & Scale pillar: OVID posts -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OVID generates $1.5M in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, OVID deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.
OVID screens cheaper on headline valuation multiples. OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OVID (-35.4% ROE) versus PYPD (-243.6% ROE) capital efficiency.
In options market volatility and institutional positioning, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 99% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.